ROARABLE
FREE $100K
My Trading Account →
▾
Trading Account Active
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / HSCS / news
LFWD (32) CUPR (21) CLGN (41) RGNT (31) ⌘ Pro Terminal →

Why HSCS Stock dropped -9.67% Today — RQD Quant Desk Flash

$2.99 -9.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.93

HeartSciences Inc. (HSCS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $16.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HSCS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HSCS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, HeartSciences Inc. (NASDAQ: HSCS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.99 (-9.67% 1D, market cap $16.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, HSCS ranks #518 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HSCS compare to LFWD and CUPR in the Health Care sector?
▼

Within the Health Care sector (Industrial Specialties), HSCS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 59.1%, and ROIC of -35.0%. By comparison, LFWD (Lifeward Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $16.9M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, HSCS leads on earnings multiple (N/A) while HSCS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HSCS?
▼

Per HSCS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001468492), HeartSciences Inc. generated $4.3K in revenue (-0.7% YoY), -$9.1M in net income, and -$7.4M in free cash flow against $4.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.93 (-1.93%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510038
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (9)SEC (8)Macro (11)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$6 Bull$3 Base$2 Bear
📬 FREE HSCS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HSCS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY HSCS SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (29% of score)

FRED Regime × Technicals: 38% of 52W Range • RSI-14 at 47.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$3.09+1.3% Next Q
Q2 (-2Q)
43
Grade D$3.13+4.8% Next Q
Q3 (-1Q)
41
Grade D$3.28-8.8% Next Q
Current
38
Grade D-$2.99-7.8% Hist 90D α
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HSCS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HSCS currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.63) and Max Pain ($3.14) forces dealer call-delta covering toward $5.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HSCS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HSCS Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why HSCS Stock dropped -9.67% Today — RQD Quant Desk Flash

HeartSciences Inc. (HSCS) dropped -9.67% to $2.99, trading at 38% of its 52-week range ($1.63 – $5.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 38% of its 52-week range ($1.63 – $5.25) with RSI-14 at 47.8 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.99 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 0.3% gross margin and $0 annual free cash flow.
Live HSCS Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HSCS)

  • ✓Walkthrough of HSCS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
HSCS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +46.57%▲ ASCENDING CHANNEL
2026-11-03O $3.61H $3.61L $2.99C $2.99VOL 54.5K
RES: $6.00SUP: $2.21SMA50: $3.63SMA200: $2.72
$5.50$4.45$3.40$2.35$1.30RES $6.00SUP $2.21$2.992026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HSCS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HSCS Butterfly Map → + Track HSCS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -0.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HSCS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HSCS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HSCS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HSCS)

Health Care Rank #518 of 1015 ⚔️ LFWD vs HSCS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HSCS vs. LFWD, CUPR, CLGN, RGNT)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, HeartSciences Inc. (HSCS) ranks #518 by composite RQD confidence (38/100, grade D-) and #848 by equity capitalization ($16.0M). Within this direct 5-issuer industry benchmark cohort, HSCS leads on earnings valuation at N/A trailing P/E, while HSCS leads on capital efficiency and profitability with -35.0% ROIC and 59.1% gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with HSCS at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HSCS ACTIVE
HeartSciences Inc.
D- 38/100 — 59.1% -35.0% -9.67% $16.0M Benchmark Subject
LFWD
Lifeward Ltd.
E 32/100 — 96.0% -35.0% +1.82% $16.9M /lfwd-vs-hscs →
CUPR
Cuprina Holdings (Cayman) Limited (Class A)
E 21/100 — -1.3% -35.0% +3.96% $13.5M /cupr-vs-hscs →
CLGN
CollPlant Biotechnologies Ltd
D- 41/100 — 64.8% -35.0% -1.33% $11.9M /clgn-vs-hscs →
RGNT
Regentis Biomaterials Ltd.
E 31/100 — — -35.0% 0.00% $9.6M /rgnt-vs-hscs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001468492 ↗

In its most recent audited fiscal period (FY2025, filed 2026-04-30), HeartSciences Inc. (HSCS) reported GAAP revenue of $4.3K (-0.7% vs. FY2024 revenue of $4.3K , and -76.8% cumulative change since FY2023) , GAAP net income of -$9.1M, operating cash flow of -$7.4M, and free cash flow of -$7.4M (-0.2% YoY). On the balance sheet, HSCS closed FY2025 with $4.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-04-30 $4.3K -$9.1M -$7.4M -$7.4M $4.2M —
FY2024 (FY) 2025-04-30 $4.3K -$8.8M -$7.4M -$7.4M $5.7M —
FY2023 (FY) 2024-04-30 $18.6K -$6.6M -$6.1M -$6.1M — —

3. HSCS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HSCS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, HeartSciences Inc. (NASDAQ: HSCS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.99 (-9.67% 1D, market cap $16.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, HSCS ranks #518 in composite RQD confidence.

How does HSCS compare to LFWD and CUPR in the Health Care sector?

Within the Health Care sector (Industrial Specialties), HSCS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 59.1%, and ROIC of -35.0%. By comparison, LFWD (Lifeward Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $16.9M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, HSCS leads on earnings multiple (N/A) while HSCS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HSCS?

Per HSCS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001468492), HeartSciences Inc. generated $4.3K in revenue (-0.7% YoY), -$9.1M in net income, and -$7.4M in free cash flow against $4.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HSCS trading relative to its 50-day, 200-day, and 52-week technical levels?

HSCS last traded at $2.99 (-9.67% on volume of 69,925 shares), positioning the stock -17.63% below its 50-day simple moving average ($3.63) and +9.93% above its 200-day simple moving average ($2.72). Across its 52-week range of $1.63 to $5.25, HSCS sits at the 37.6% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.62 to $3.36).

Direct Sub-Reports: HSCS RQD Cockpit HSCS 12M Forecast HSCS Earnings & Move HSCS Dividends & DRIP HSCS Insiders & 13F HSCS Whale Options HSCS Profit Sankey HSCS News & Why
ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

HSCS — HeartSciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-04-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

HeartSciences Inc. (HSCS) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.99 (-9.67% 1D, market capitalization $16.0M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 59.1%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

HeartSciences Inc. Is a NASDAQ-listed company classified under the Health Care sector and the Industrial Specialties industry. Reported revenue is — across the periods provided, with gross margin listed at 59.1%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-04-30), HeartSciences Inc. (HSCS) reported $4.3K in annual revenue (up from $4.3K in FY2024, -0.7% YoY) and -$9.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($18.6K revenue, -$6.6M net income) through FY2025, HSCS scaled operating cash flow to -$7.4M and free cash flow to -$7.4M, backed by $4.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $1.63 – $5.25 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be mapped from the source data. Sector correlation beyond the stated beta of 1. The principal second-order exposure a prospective investor should monitor is the pending business combination, since headlines link HSCS to a counterparty in a different sector, and the outcome of that transaction could reshape the company's identity and capital structure.

  • Key Question #1: Can HSCS sustain or expand its -60.0% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.3K and free cash flow of -$7.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is HSCS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HSCS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for HeartSciences Inc. (HSCS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HSCS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HSCS Bull vs. Bear Conversation Board — What's Your Call at $2.99?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HSCS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HSCS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $3.97 (+19.9%)
📌 Pinned Debate

The pending business combination with Fortitude Mining could reshape the company's capital base and listing profile.

Long HSCS at $3.31 targeting $3.97. The pending business combination with Fortitude Mining could reshape the company's capital base and listing profile.. Institutional whale score is 9/20 and the risk/reward vs. the $1.63 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

@MeanReversion_88 Shorting a 9/20 institutional whale-flow stock at $3.31 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $2.65 (-19.9%)
Spot @ $3.31

Negative ROIC of -35%, zero FCF yield, and cash falling to $1.1M against a $7.4M annual FCF outflow signal near-term funding strain.

I respect the product at HeartSciences Inc., but the stock at $3.31 is a different story. Negative ROIC of -35%, zero FCF yield, and cash falling to $1.1M against a $7.4M annual FCF outflow signal near-term funding strain.. FCF yield is 0.0% and RQD sits at 38/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE